Co-Founder and CEO
Dr. Tomasz Sablinski, MD, PhD is the CEO & Director of Transparency Life Sciences, LLC. Dr. Sablinski serves as the Managing Director, Head of Clinical Development at Auven Therapeutics Management L.L.L.P. Dr. Sablinski joined Celtic Therapeutics on December 19, 2008. Dr. Sablinski joined CTD with 28 of experience in healthcare, including his last fifteen years in the global pharmaceutical industry. His career includes ten years of clinical practice as a surgeon specializing in renal transplantation and general surgery, and several years of basic research in immunobiology. Prior to joining CTD, Dr. Sablinski served as Vice President of Novartis Pharmaceuticals Corp. in charge of US Clinical Development and Medical Affairs. Prior to this, Dr. Sablinski held several leadership positions at Novartis headquarters including Vice President of Clinical Research and Development and Head of Global-Japanese Coordination. He also held multiple leadership positions in Novartis’ Transplantation Business Unit. Dr. Sablinski served as Vice President of Novartis AG. He participated in, and supervised numerous NDA and IND submissions in the US, Europe and Japan. Dr. Sablinski began his career in the Pharmaceutical industry as a consultant to several biotechnology companies in the mid-nineties. At this time he was also a Medical Director at Parexel International. He serves as a Member of Advisory Board at New Ventures Funds. He serves as Member of Business Advisory Board at Shade. Prior to joining pharmaceutical industry he conducted basic research while appointed as Instructor of Surgery at Harvard Medical School, Massachusetts General Hospital, and Fellow at the Brigham and Women’s Hospital in Boston. His other clinical appointments include Lahey Clinic, Burlington, MA, and Central Clinical Hospital in Warsaw, Poland. Dr. Sablinski earned his MD and his Ph.D. in Transplant Immunology at Warsaw Medical School and his Bachelor degrees at Copernicus College in Warsaw, Poland.